On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback